Trials / Conditions / Carcinoma, Transitional Cell

Carcinoma, Transitional Cell

31 registered clinical trials studyying Carcinoma, Transitional Cell — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract NCT07218380	Eli Lilly and Company	Phase 3
Not Yet Recruiting	Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC NCT07189793	First Affiliated Hospital of Wenzhou Medical University	Phase 2
Recruiting	uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto NCT05874921	UroGen Pharma Ltd.	—
Unknown	A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma NCT05318339	Chinese Academy of Medical Sciences	Phase 2
Terminated	A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer ( NCT05014139	Astellas Pharma Global Development, Inc.	Phase 1
Active Not Recruiting	CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors NCT04660929	Carisma Therapeutics Inc	Phase 1
Completed	Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Po NCT03410693	Bayer	Phase 2 / Phase 3
Terminated	A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer NCT03288545	Astellas Pharma Global Development, Inc.	Phase 1 / Phase 2
Completed	A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer NCT03219333	Astellas Pharma Inc	Phase 2
Completed	The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study NCT02793128	UroGen Pharma Ltd.	Phase 3
Completed	Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With NCT03051373	Chinese PLA General Hospital	Phase 2
Completed	Neoadjuvant Atezolizumab in Localized Bladder Cancer NCT02451423	Lawrence Fong	Phase 2
Terminated	A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive NCT02450331	Hoffmann-La Roche	Phase 3
Completed	A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitio NCT02443324	Eli Lilly and Company	Phase 1
Completed	Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer NCT02300610	H. Lee Moffitt Cancer Center and Research Institute	Phase 1
Completed	Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid T NCT02014337	Corcept Therapeutics	Phase 1
Terminated	Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Ch NCT01856101	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Phase 2
Completed	Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer NCT01529411	Spanish Oncology Genito-Urinary Group	Phase 2
Completed	A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Re NCT01478685	Celgene	Phase 1
Unknown	Tesetaxel for Previously Treated Patients With Bladder Cancer NCT01215877	Genta Incorporated	Phase 2
Unknown	The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma NCT01189838	Far Eastern Memorial Hospital	—
Completed	Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Blad NCT00722553	Acrotech Biopharma Inc.	Phase 2
Withdrawn	Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma NCT00172367	National Taiwan University Hospital	Phase 2
Unknown	Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure NCT00109655	Cell Genesys	Phase 1
Terminated	Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer NCT04039867	University of California, Irvine	Phase 2
Completed	Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladde NCT00101842	Eli Lilly and Company	Phase 1 / Phase 2
Completed	2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen NCT00191971	Eli Lilly and Company	Phase 2
Completed	TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Uroth NCT00077688	Achieve Life Sciences	Phase 2
Terminated	Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract NCT00127595	Gustave Roussy, Cancer Campus, Grand Paris	Phase 2
Unknown	Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer NCT00146276	Association of Urologic Oncology (AUO)	Phase 3
Completed	A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder NCT00001381	National Cancer Institute (NCI)	Phase 1